SCHEDULE: Celadon Partners Eyes Senti Bio Board Seats, Financing

Celadon Partners, holding 45% of Senti Biosciences, is in discussions for a potential financing deal and board representation, signaling strategic changes.

Summary

• Celadon Partners SPV 24 and Celadon Partners, LLC (the "Reporting Persons") beneficially own 13,404,441 shares of Senti Biosciences, Inc. common stock.
• This represents 45.0% of the outstanding common stock, calculated based on 26,160,206 shares outstanding as of July 31, 2025.
• The ownership includes 3,627,441 shares issuable upon exercise of warrants, subject to a 45% beneficial ownership limitation cap.
• The Reporting Persons are engaged in preliminary discussions with Senti Biosciences regarding a potential financing transaction.
• These discussions may involve changes to the Issuer's capital structure and the composition of its board of directors, potentially including additional board representation for the Reporting Persons.
• They may also discuss strategic alternatives such as business combinations, a sale of the Issuer, acquisitions, or investments.

Sentiment

Score: 7

Explanation: The filing indicates active engagement from a significant shareholder (45% ownership) in discussions about potential financing and strategic changes, including board representation. This suggests a proactive approach to enhancing shareholder value, which is generally positive. However, the 'potential' nature of these discussions and the possibility of changes to capital structure or board composition introduce an element of uncertainty.

Positives

• A significant investor (Celadon Partners) is actively engaged in discussions with Senti Biosciences, potentially indicating a commitment to enhancing shareholder value.
• The pursuit of a potential financing transaction could provide necessary capital for the Issuer.

Risks

• Uncertainty regarding the outcome of discussions for a potential financing transaction.
• Potential changes to the Issuer's capital structure could dilute existing shareholders or alter financial leverage.
• Changes to the composition of the board of directors could lead to shifts in strategic direction or management.
• The Reporting Persons may purchase additional securities, sell some or all of their holdings, engage in short selling, or hedging, which could impact share price volatility.
• The Reporting Persons' plans and proposals may change at any time.

Future Outlook

The Reporting Persons intend to continue preliminary discussions with Senti Biosciences regarding a potential financing transaction and changes to the Issuer's capital structure and board composition. They will continuously review their investment and may take various actions, including buying or selling securities, engaging in short selling or hedging, or pursuing strategic alternatives for the Issuer. Their plans may change at any time based on market conditions and the Issuer's performance.

Industry Context

This filing indicates significant investor interest and potential strategic shifts for Senti Biosciences, a biotechnology company. Such investor activism and potential capital structure changes are common in the biotech sector, where companies often require substantial funding for R&D and face high risks and long development cycles.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through strategic initiatives or financing, but also risk of dilution from capital raises or changes in share price due to investor actions (buying/selling).
• Management/Board: Potential for changes in board composition and strategic direction, which could impact current management's roles and responsibilities.
• Creditors: Potential impact from changes to the Issuer's capital structure.

Next Steps

• Continue preliminary discussions with Senti Biosciences regarding a potential financing transaction.
• Discuss changes to the Issuer's capital structure and board of directors.
• Engage in discussions with various stakeholders regarding the Issuer's business, management, capital structure, corporate governance, and strategic alternatives.
• Review investment in the Issuer on a continuing basis.
• Potentially purchase additional securities, sell existing holdings, engage in short selling or hedging, or take other actions with respect to the investment.

Key Dates

Recommendation

The filing indicates significant investor interest and potential strategic changes, including financing and board representation. While these discussions could lead to positive outcomes for Senti Biosciences, they are still preliminary and introduce uncertainty regarding the final terms and impact on the company's valuation and future direction. A "hold" recommendation is appropriate given the potential for both positive developments and risks associated with capital structure and governance changes, advising investors to await more concrete details before making further investment decisions.

Keywords

Senti Biosciences, Celadon Partners, Schedule 13D, Beneficial Ownership, Biotechnology, Financing, Board Representation, Capital Structure, Strategic Alternatives, Warrants